磺酰脲类药物。

Sulfonylureas.

作者信息

Zimmerman B R

机构信息

Department of Internal Medicine, Mayo Medical School, Mayo Clinic, Rochester, Minnesota, USA.

出版信息

Endocrinol Metab Clin North Am. 1997 Sep;26(3):511-22. doi: 10.1016/s0889-8529(05)70264-4.

DOI:10.1016/s0889-8529(05)70264-4

PMID:9314012

Abstract

Sulfonylureas have been available for the treatment of non-insulin-dependent diabetes mellitus (NIDDM) since the 1950s. With the introduction of new oral agents, there is a tendency to discount the value of sulfonylurea therapy. Sulfonylureas have the advantage of multiple formulations, low costs, minimal side effects, and demonstrated efficacy in controlling hyperglycemia. The major disadvantage of sulfonylureas is secondary failure, which may occur with all oral agents as part of the progression of NIDDM. Sulfonylureas should continue to play an important role in the treatment of NIDDM.

摘要

自20世纪50年代以来，磺脲类药物一直用于治疗非胰岛素依赖型糖尿病（NIDDM）。随着新型口服药物的出现，人们倾向于低估磺脲类药物治疗的价值。磺脲类药物具有多种剂型、成本低、副作用小以及在控制高血糖方面疗效已得到证实等优点。磺脲类药物的主要缺点是继发性失效，这在所有口服药物治疗中都可能作为NIDDM病情进展的一部分而出现。磺脲类药物应继续在NIDDM的治疗中发挥重要作用。